Tag Archives: IgA nephropathy

Novartis Reports Positive Results for Atrasentan in IgA Nephropathy Study

(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release